leadf
logo-loader
viewOutlook Therapeutics
(
NASDAQ:OTLK
)

Outlook Therapeutics 'almost complete' with pivotal Phase 3 NORSE TWO trial to treat wet AMD

Outlook Therapeutics, Inc (NASDAQ:OTLK) Lawrence Kenyon updated Proactive on the Monmouth, New Jersey-based biotech group's recent clinical advances. Kenyon says the group, who recently reported a positive safety profile in its NORSE THREE open-label safety study to treat wet AMD, says the group is almost complete with its pivotal Phase 3 NORSE TWO trial, expected to report that data in 3Q of 2021. Later within the year, it will then submit a BLA filing.

Quick facts: Outlook Therapeutics

Follow
NASDAQ:OTLK

Price: 2.38 USD

Market Cap: $417.31 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Empower Clinic’s Medi-Collective expands future locations to 33 covering BC,...

Empower Clinics CEO Steven McAuley joined Steve Darling from Proactive to shares news the company is expanding their national clinic rollout strategy and are preparing to open their next Medi-Collective" clinic in Etobicoke, Ontario on October 18th. McAuley also shared with Proactive the...

1 hour, 28 minutes ago

2 min read